Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / IBI363 Shows Survival Benefits in NSCLC
Tech clinical trial results

IBI363 Shows Survival Benefits in NSCLC

Analysis based on 9 articles · First reported May 21, 2026 · Last updated Jun 01, 2026

Sentiment
70
Attention
6
Articles
9
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive long-term clinical trial results for IBI363 in advanced immunotherapy-resistant non-small cell lung cancer are expected to positively impact the stock prices of Innovent Biologics and Takeda Pharmaceutical Company. The progression to global Phase 3 studies and the potential for a new treatment option in a high-unmet-need area signal future revenue growth and market share for both companies.

Biotechnology Pharmaceuticals
Event Summary

Innovent Biologics announced updated long-term follow-up data from its Phase 1 PoC clinical study of IBI363 (PD-1/IL-2 bispecific fusion protein) in advanced immunotherapy-resistant non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data showed robust overall survival benefits with a long tail effect in both squamous NSCLC and adenoNSCLC, particularly in patients with a smoking history. IBI363 demonstrated a favorable safety profile. Based on these results, IBI363 has entered a global Phase 3 clinical study for IO-resistant squamous NSCLC, with plans for another global Phase 3 study for non-squamous NSCLC. Innovent Biologics and Takeda Pharmaceutical Company are co-developing IBI363 globally, with Takeda Pharmaceutical Company holding exclusive commercialization rights outside the U.S. and greater China. IBI363 has received Fast Track Designations from the United States — Food and Drug Administration and Breakthrough Therapy Designations from the China — National Medical Products Administration of China.

Key Actions
90 Innovent Biologics presented updated data American Society of Clinical Oncology
80 Innovent Biologics entered global Phase 3 study
70 Innovent Biologics co-developed IBI363 Takeda Pharmaceutical Company
60 United States — Food and Drug Administration granted Fast Track Designations Innovent Biologics
60 China — National Medical Products Administration granted Breakthrough Therapy Designations Innovent Biologics
Entities Involved
stock
Innovent Biologics
Innovent Biologics is the developer and co-commercializer of IBI363, and the positive long-term clinical trial results enhance its product pipeline and market position in oncology. The company's stock performance is likely to benefit from these favorable outcomes and the progression to global Phase 3 studies.
Importance 100 Sentiment 75
stock
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company is co-developing IBI363 with Innovent Biologics and will exclusively commercialize it globally outside the U.S. and greater China. The positive clinical results for IBI363 strengthen Takeda's oncology portfolio and future revenue potential.
Importance 80 Sentiment 60
ngo
American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) Annual Meeting is the platform where the updated clinical data for IBI363 was presented, providing a significant forum for disseminating these important findings to the medical and scientific community.
Importance 30 Sentiment 0
cnt
China
China is the location where the initial PoC clinical study for IBI363 was conducted and where Innovent Biologics is based. The China NMPA has also granted Breakthrough Therapy Designations for IBI363.
Importance 20 Sentiment 0
cnt
United States
The United States is a key market for IBI363, with Innovent Biologics and Takeda Pharmaceutical Company co-commercializing the drug there. The U.S. FDA has granted Fast Track Designations for IBI363.
Importance 20 Sentiment 0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration (FDA) has granted two Fast Track Designations to IBI363, indicating its potential to address unmet medical needs and expedite its development and review process.
Importance 20 Sentiment 0
govactor
China — National Medical Products Administration
The China — National Medical Products Administration (NMPA) of China has granted three Breakthrough Therapy Designations to IBI363, recognizing its potential for significant clinical advantage over existing therapies.
Importance 20 Sentiment 0
per
Jianya Zhou
Jianya Zhou, a professor from The First Affiliated Hospital, School of Medicine, Zhejiang University, provided expert commentary on the significance of IBI363's clinical benefits in immunotherapy-resistant NSCLC.
Importance 10 Sentiment 0
loc
China — Huizhou
China — Huizhou, Chief R&D Officer (Oncology Pipeline) of Innovent Biologics, expressed enthusiasm for IBI363's potential to offer a new treatment option and long-term survival benefits for patients with NSCLC.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.